74 research outputs found
Investigating REPAIRv2 as a Tool to Edit CFTR mRNA with Premature Stop Codons
Cystic fibrosis (CF) is caused by mutations in the gene encoding the transmembrane
conductance regulator (CFTR) protein. Some CF patients are compound heterozygous or homozygous
for nonsense mutations in the CFTR gene. This implies the presence in the transcript of premature
termination codons (PTCs) responsible for a truncated CFTR protein and a more severe form
of the disease. Aminoglycoside and PTC124 derivatives have been used for the read-through
of PTCs to restore the full-length CFTR protein. However, in a precision medicine framework,
the CRISPR/dCas13b-based molecular tool “REPAIRv2” (RNA Editing for Programmable A to I
Replacement, version 2) could be a good alternative to restore the full-length CFTR protein. This RNA
editing approach is based on the targeting of the deaminase domain of the hADAR2 enzyme fused to
the dCas13b protein to a specific adenosine to be edited to inosine in the mutant mRNA. Targeting
specificity is allowed by a guide RNA (gRNA) complementarily to the target region and recognized
by the dCas13b protein. Here, we used the REPAIRv2 platform to edit the UGA PTC to UGG in
dierent cell types, namely IB3-1 cells, HeLa, and FRT cells engineered to express H2BGFPopal and
CFTRW1282X, respectively
Multiplex ligation-dependent probe amplification detection of an unknown large deletion of the CREB-binding protein gene in a patient with Rubinstein-Taybi syndrome
Rubinstein-Taybi syndrome is a rare autosomal dominant congenital disorder characterized by postnatal growth retardation, psychomotor developmental delay, skeletal anomalies, peculiar facial morphology, and tumorigenesis. Mutations in the gene encoding the cAMP response element-binding protein (CREB, also known as CREBBP or CBP) on chromosome 16p13.3 have been identified. In addition, some patients with low intelligence quotients and autistic features bear large deletions. Based on these observations, we used multiplex ligation-dependent probe amplification to search for large deletions affecting the CREBBP gene in a Rubinstein-Taybi syndrome patient. We identified a novel heterozygote deletion removing five exons (exons 17-21), encoding the histone acetyltransferase domain. We propose the use of multiplex ligation-dependent probe amplification as a fast, accurate and cheap test for detecting large deletions in the CREBBP gene in the sub-group of Rubinstein-Taybi syndrome patients with low intelligence quotients and autistic features
Analysis of the gastrin-releasing peptide receptor gene in Italian patients with autism spectrum disorders
The gastrin-releasing peptide receptor (GRPR) was implicated for the first time in the pathogenesis of Autism spectrum disorders (ASD) by Ishikawa-Brush et al. [Ishikawa-Brush et al. (1997): Hum Mol Genet 6: 1241-1250]. Since this original observation, only one association study [Marui et al. (2004): Brain Dev 26: 5-7] has further investigated, though unsuccessfully, the involvement of the GRPR gene in ASD. With the aim of contributing further information to this topic we have sequenced the entire coding region and the intron/exon junctions of the GRPR gene in 149 Italian autistic patients. The results of this study led to the identification of four novel point mutations, two of which, that is, C6S and L181F, involve amino acid changes identified in two patients with ASD and Rett syndrome, respectively. Both the leucine at position 181 and the cysteine at position 6 are strongly conserved in vertebrates. C6S and L181F mutant proteins were expressed in COS-7 and BALB/3T3 cells, but they did not affect either GRP's binding affinity or its potency for stimulating phospholipase C-mediated production of inositol 1,4,5-trisphosphate. In summary, our results do not provide support for a major role of the GRPR gene in ASD in the population of patients we have studied. However, there is a potential role of C6S and L181F mutations on GRPR function, and possibly in the pathogenesis of the autistic disorders in the two patient
HERMIA: An Heterogeneous and Reconfigurable Machine for Image Analysis
In this paper is described the general architecture of an Heterogeneous and Reconfigurable Machine for Image Analysis (HERMIA); the first prototype of the system has
been developed at the University of Palermo. Conventional hardware has been used in order to emulate the machine and evaluate the system performance
Preliminary results are presented and discussed
Defects in insulin-receptor internalization and processing in monocytes of obese subjects and obese NIDDM patients
We investigated intracellular processing of the insulin-receptor complex in monocytes from 12 healthy control subjects, 11 obese nondiabetic subjects, and 13 obese patients with non-insulin-dependent diabetes mellitus (NIDDM) by measuring receptor internalization, recovery of cell-surface insulin binding after receptor internalization, and the release of intracellular intact insulin (insulin retroendocytosis). When monocytes from the three groups of subjects were exposed to 100 nM unlabeled insulin for 30 min at 37°C, the subsequent cell-surface 125I-labeled insulin binding was reduced, but the total number of insulin receptors, measured by radioimmunoassay, was not changed. These findings indicate a redistribution of insulin receptors from the surface to the cell interior. Insulin-receptor internalization was significantly lower in monocytes of obese NIDDM patients (mean ± SE 17.8 ± 4.7%) than in obese subjects and healthy control subjects (33.5 ± 4.5%, P < .05, and 34.4 ± 3.7%, P < .02, respectively). Moreover, in downregulated cells, a complete recovery of the initial insulin binding was observed in control subjects but not in obese NIDDM patients or obese nondiabetic subjects. The release of internalized insulin was also reduced in obese NIDDM patients and obese subjects (t( 1/2 ) = 49.0 ± 2.4 min, P < .02; 47.4 ± 5.7 min, P < .05; and 32.9 ± 3.8 in NIDDM patients, obese subjects, and control subjects, respectively). In the radioactivity released from monocytes of obese subjects and obese NIDDM patients, the percentage of intact insulin was higher (P < .05) than in control subjects, suggesting reduced intracellular insulin degradation in obese subjects and obese NIDDM patients. This study indicates that insulin-resistant obese subjects and obese NIDDM patients have multiple postbinding defects of the insulin-receptor intracellular processing. Among these defects, decreased insulin-receptor internalization is specifically associated with diabetic patients
- …